{"organizations": [], "uuid": "a9b0f72bc9dcac2a80f76b1a428413e270d33b9b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/esperion-thera-study/esperions-cholesterol-drug-succeeds-in-late-stage-study-idUSL4N1QO5FV", "country": "US", "domain_rank": 408, "title": "Esperion's cholesterol drug succeeds in late-stage study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.828, "site_type": "news", "published": "2018-03-07T20:31:00.000+02:00", "replies_count": 0, "uuid": "a9b0f72bc9dcac2a80f76b1a428413e270d33b9b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/esperion-thera-study/esperions-cholesterol-drug-succeeds-in-late-stage-study-idUSL4N1QO5FV", "ord_in_thread": 0, "title": "Esperion's cholesterol drug succeeds in late-stage study", "locations": [], "entities": {"persons": [{"name": "michael yee", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "esperion therapeutics inc", "sentiment": "negative"}, {"name": "esperion", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.\nEsperion is looking to target patients who are unable to take or do not show improvement with statins, a class of medicines that lower the level of low-density lipoprotein cholesterol (LDL-C) in the blood.\nAlthough less potent than PCSK9 inhibitors - newer, injected cholesterol medicines usually prescribed to such patients - Esperion’s drug is expected to be cheaper.\nEsperion’s 12-week study tested a 180 mg per day dose of its drug, bempedoic acid, versus a placebo in 269 patients with high cholesterol whose treatments were not adequate.\n“Positive data would increase the likelihood of a global partnership or M&A takeout, since Esperion has wholly owned rights to an asset that could fit well in a big pharma,” Jefferies analyst Michael Yee said in a client note ahead of the results. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T20:31:00.000+02:00", "crawled": "2018-03-08T17:08:54.031+02:00", "highlightTitle": ""}